Mosunetuzumab and lymphoma: latest updates from 2022 ASH annual meeting

Bispecific antibodies are emerging as a promising new immunotherapy modality and are actively being evaluated in clinical trials for patients with lymphoma. As the first BsAb to receive regulatory approval for lymphoma, mosunetuzumab, an antiCD20/anti-CD3 BsAb, is an exciting new option for patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Yang, Marcucci, Emanuela C., Budde, Lihua E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10308681/
https://www.ncbi.nlm.nih.gov/pubmed/37381053
http://dx.doi.org/10.1186/s13045-023-01462-0
_version_ 1785066296929419264
author Cao, Yang
Marcucci, Emanuela C.
Budde, Lihua E.
author_facet Cao, Yang
Marcucci, Emanuela C.
Budde, Lihua E.
author_sort Cao, Yang
collection PubMed
description Bispecific antibodies are emerging as a promising new immunotherapy modality and are actively being evaluated in clinical trials for patients with lymphoma. As the first BsAb to receive regulatory approval for lymphoma, mosunetuzumab, an antiCD20/anti-CD3 BsAb, is an exciting new option for patients with relapsed or refractory (R/R) follicular lymphoma. The approval was based on results from an international, multicenter, phase 2 trial in patients with relapsed or refractory (R/R) follicular lymphoma following at least 2 prior lines of systemic therapy. Mosunetuzumab demonstrated remarkable efficacy with an overall response rate of 80% and complete response rate of 60%. Here we provided an overview of the latest clinical data on mosunetuzumab in lymphoma presented at the 2022 ASH Annual Meeting.
format Online
Article
Text
id pubmed-10308681
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-103086812023-06-30 Mosunetuzumab and lymphoma: latest updates from 2022 ASH annual meeting Cao, Yang Marcucci, Emanuela C. Budde, Lihua E. J Hematol Oncol Correspondence Bispecific antibodies are emerging as a promising new immunotherapy modality and are actively being evaluated in clinical trials for patients with lymphoma. As the first BsAb to receive regulatory approval for lymphoma, mosunetuzumab, an antiCD20/anti-CD3 BsAb, is an exciting new option for patients with relapsed or refractory (R/R) follicular lymphoma. The approval was based on results from an international, multicenter, phase 2 trial in patients with relapsed or refractory (R/R) follicular lymphoma following at least 2 prior lines of systemic therapy. Mosunetuzumab demonstrated remarkable efficacy with an overall response rate of 80% and complete response rate of 60%. Here we provided an overview of the latest clinical data on mosunetuzumab in lymphoma presented at the 2022 ASH Annual Meeting. BioMed Central 2023-06-28 /pmc/articles/PMC10308681/ /pubmed/37381053 http://dx.doi.org/10.1186/s13045-023-01462-0 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Correspondence
Cao, Yang
Marcucci, Emanuela C.
Budde, Lihua E.
Mosunetuzumab and lymphoma: latest updates from 2022 ASH annual meeting
title Mosunetuzumab and lymphoma: latest updates from 2022 ASH annual meeting
title_full Mosunetuzumab and lymphoma: latest updates from 2022 ASH annual meeting
title_fullStr Mosunetuzumab and lymphoma: latest updates from 2022 ASH annual meeting
title_full_unstemmed Mosunetuzumab and lymphoma: latest updates from 2022 ASH annual meeting
title_short Mosunetuzumab and lymphoma: latest updates from 2022 ASH annual meeting
title_sort mosunetuzumab and lymphoma: latest updates from 2022 ash annual meeting
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10308681/
https://www.ncbi.nlm.nih.gov/pubmed/37381053
http://dx.doi.org/10.1186/s13045-023-01462-0
work_keys_str_mv AT caoyang mosunetuzumabandlymphomalatestupdatesfrom2022ashannualmeeting
AT marcucciemanuelac mosunetuzumabandlymphomalatestupdatesfrom2022ashannualmeeting
AT buddelihuae mosunetuzumabandlymphomalatestupdatesfrom2022ashannualmeeting

Ejemplares similares